Since KRAS was found to be involved in lipogenesis inducing fatty acid synthesis [32], different phase I trials demonstrated promising preliminary results of fatty acid synthase (FASN) inhibitors in KRAS-mutant NSCLC [33,34,35]. The gene discussed is FASN; the disease is non-small cell lung carcinoma.